Fig. 1

Trabectedin dose and schedule modifications. a Reasons for dose reductions (n = 15 patients, 19.5 %). b Reasons for schedule delay (n = 31, 40.3 %). Number of delayed cycles per patient: one (n = 25, 80.7 %), two (n = 5, 16.1 %) and three (n = 1, 3.2 %). c Reasons to discontinue trabectedin (n = 72, 93.5 %). Abbreviations: ANC, absolute neutrophil count; CK, creatine kinase